Two highly anticipated oral presentations captured attention: first pivotal study of sunvozertinib (WU-KONG6) and multinational pivotal study of golidocitinib (JACKPOT8) Sunvozertinib achieved an ORR of 60.8% in ≥ second-line treatment and 77.8% in the first-line treatment for EGFR…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.